Literature DB >> 31391235

Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids.

Ross W Cheloha1, Andrew W Woodham1, Djenet Bousbaine1,2, Tong Wang3, Shi Liu3, John Sidney4, Alessandro Sette4,5, Samuel H Gellman6, Hidde L Ploegh7.   

Abstract

Proteins are composed of α-amino acid residues. This consistency in backbone structure likely serves an important role in the display of an enormous diversity of peptides by class II MHC (MHC-II) products, which make contacts with main chain atoms of their peptide cargo. Peptides that contain residues with an extra carbon in the backbone (derived from β-amino acids) have biological properties that differ starkly from those of their conventional counterparts. How changes in the structure of the peptide backbone affect the loading of peptides onto MHC-II or recognition of the resulting complexes by TCRs has not been widely explored. We prepared a library of analogues of MHC-II-binding peptides derived from OVA, in which at least one α-amino acid residue was replaced with a homologous β-amino acid residue. The latter contain an extra methylene unit in the peptide backbone but retain the original side chain. We show that several of these α/β-peptides retain the ability to bind tightly to MHC-II, activate TCR signaling, and induce responses from T cells in mice. One α/β-peptide exhibited enhanced stability in the presence of an endosomal protease relative to the index peptide. Conjugation of this backbone-modified peptide to a camelid single-domain Ab fragment specific for MHC-II enhanced its biological activity. Our results suggest that backbone modification offers a method to modulate MHC binding and selectivity, T cell stimulatory capacity, and susceptibility to processing by proteases such as those found within endosomes where Ag processing occurs.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31391235      PMCID: PMC6736755          DOI: 10.4049/jimmunol.1900536

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

Review 1.  Proteolysis in MHC class II antigen presentation: who's in charge?

Authors:  J A Villadangos; H L Ploegh
Journal:  Immunity       Date:  2000-03       Impact factor: 31.745

2.  DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope.

Authors:  J M Robertson; P E Jensen; B D Evavold
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.

Authors:  D R Bolin; A L Swain; R Sarabu; S J Berthel; P Gillespie; N J Huby; R Makofske; L Orzechowski; A Perrotta; K Toth; J P Cooper; N Jiang; F Falcioni; R Campbell; D Cox; D Gaizband; C J Belunis; D Vidovic; K Ito; R Crowther; U Kammlott; X Zhang; R Palermo; D Weber; J Guenot; Z Nagy; G L Olson
Journal:  J Med Chem       Date:  2000-06-01       Impact factor: 7.446

4.  Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33.

Authors:  C Stemmer; A Quesnel; A Prévost-Blondel; C Zimmermann; S Muller; J P Briand; H Pircher
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

5.  Role of peptide backbone in T cell recognition.

Authors:  S Calbo; G Guichard; P Bousso; S Muller; P Kourilsky; J P Briand; J P Abastado
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

Review 6.  Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation.

Authors:  P G Medd; B M Chain
Journal:  Semin Cell Dev Biol       Date:  2000-06       Impact factor: 7.727

7.  Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.

Authors:  G Guichard; A Zerbib; F A Le Gal; J Hoebeke; F Connan; J Choppin; J P Briand; J G Guillet
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

Review 8.  Proteolysis and class I major histocompatibility complex antigen presentation.

Authors:  I A York; A L Goldberg; X Y Mo; K L Rock
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

9.  Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.

Authors:  A Quesnel; A Zerbib; F Connan; J G Guillet; J P Briand; J Choppin
Journal:  J Pept Sci       Date:  2001-03       Impact factor: 1.905

10.  Beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope.

Authors:  S Reinelt; M Marti; S Dédier; T Reitinger; G Folkers; J A de Castro; D Rognan
Journal:  J Biol Chem       Date:  2001-05-07       Impact factor: 5.157

View more
  4 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

2.  Effects of Single α-to-β Residue Replacements on Recognition of an Extended Segment in a Viral Fusion Protein.

Authors:  Victor K Outlaw; Dale F Kreitler; Debora Stelitano; Matteo Porotto; Anne Moscona; Samuel H Gellman
Journal:  ACS Infect Dis       Date:  2020-07-27       Impact factor: 5.084

3.  Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes.

Authors:  Ruslan Gibadullin; Caleb J Randall; John Sidney; Alessandro Sette; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2021-04-21       Impact factor: 15.419

4.  Proteomimetic surface fragments distinguish targets by function.

Authors:  Attila Tököli; Beáta Mag; Éva Bartus; Edit Wéber; Gerda Szakonyi; Márton A Simon; Ágnes Czibula; Éva Monostori; László Nyitray; Tamás A Martinek
Journal:  Chem Sci       Date:  2020-09-10       Impact factor: 9.825

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.